Showing results (41-50 of 47) with videos related to
Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
European Journal of Medicinal Chemistry|January 21, 2019
Rad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cellsMarinella Roberti, Fabrizio Schipani, Greta Bagnolini, et al.Journal of Medicinal Chemistry|January 26, 2017
Discovery of Multitarget Agents Active as Broad-Spectrum Antivirals and Correctors of Cystic Fibrosis Transmembrane Conductance Regulator for Associated Pulmonary DiseasesSabrina Tassini, Liang Sun, Kristina Lanko, et al.Chemmedchem|June 24, 2011
Toward the discovery of novel anti-HIV drugs. Second-generation inhibitors of the cellular ATPase DDX3 with improved anti-HIV activity: synthesis, structure-activity relationship analysis, cytotoxicity studies, and target validationGiovanni Maga, Federico Falchi, Marco Radi, et al.Journal of Medicinal Chemistry|February 11, 2020
Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with OlaparibGreta Bagnolini, Domenico Milano, Marcella Manerba, et al.European Journal of Medicinal Chemistry|October 15, 2017
Crassiflorone derivatives that inhibit Trypanosoma brucei glyceraldehyde-3-phosphate dehydrogenase (TbGAPDH) and Trypanosoma cruzi trypanothione reductase (TcTR) and display trypanocidal activityElisa Uliassi, Giulia Fiorani, R Luise Krauth-Siegel, et al.Cell Death Discovery|March 17, 2025
Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential activityMirco Masi, Laura Poppi, Viola Previtali, et al.Journal of Medicinal Chemistry|April 30, 2015
Studies on the ATP Binding Site of Fyn Kinase for the Identification of New Inhibitors and Their Evaluation as Potential Agents against Tauopathies and TumorsCristina Tintori, Giuseppina La Sala, Giulia Vignaroli, et al.Pageof 5